Breaking News, Trials & Filings

Mayne Pharma Submits NDA to FDA for E4/DRSP

Development and manufacturing partner Mithra can synthesise E4 at scale through a complex plant-based production process

By: Contract Pharma

Contract Pharma Staff

Mayne Pharma has submitted an NDA to the U.S. FDA seeking marketing authorization for E4/DRSP, a combined oral contraceptive indicated for the prevention of pregnancy. E4/DRSP is a novel, next-gen oral contraceptive containing Estetrol (E4) 15 mg and drospirenone (DRSP) 3 mg. E4 is a naturally occurring estrogen that is produced by the human fetal liver during pregnancy. Following more than 20 years of research and development, Mayne Pharma’s development and manufacturing partner Mithra...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters